Designation of Nitric Oxide (Inomax) as an Orphan Drug - Ikaria Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, serves as the legislative foundation for the regulation of therapeutic goods, including medicines, medical devices, and other health-related products. The Act was introduced to ensure that therapeutic goods available to the public are safe, of high quality, and effective for their intended use. The designation of nitric oxide (INOmax) as an orphan drug under this Act on 11 September 2013 by the Therapeutic Goods Administration (TGA) is a specific instance of its application, aimed at addressing the unmet medical needs of a small population suffering from rare conditions. The policy objective behind this designation is to incentivise the development of treatments for rare diseases by providing certain benefits and support to the sponsor, Ikaria Australia Pty Ltd, thereby facilitating access to potentially life-saving therapies for those in need.

Scope and Application

The Therapeutic Goods Act 1989, as amended and designated by the Therapeutic Goods Administration (TGA), pertains to the regulation of therapeutic goods in Australia. Specifically, this act applies to therapeutic goods, including drugs, medical devices, and biologicals, ensuring they meet safety, quality, and efficacy standards. The designation of nitric oxide (INOmax) as an orphan drug under this act underscores its relevance to a specific, smaller patient population, in this case, newborn infants, infants, toddlers, children, and adolescents aged 0-17 years suffering from peri-and post-operative pulmonary hypertension in conjunction with heart surgery. The geographic reach of this legislation is nationwide, applying across the Commonwealth of Australia, ensuring consistent standards and oversight across all states and territories. Notably, the application of the Therapeutic Goods Act extends to the regulation of these therapeutic goods through subordinate instruments, including the Therapeutic Goods Regulations 1990, which provide further detail and operational guidelines for the act’s provisions. This legislative framework ensures that the therapeutic goods, such as INOmax, are safe, of high quality, and meet the necessary efficacy criteria for their intended use.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides the legal framework for the regulation of therapeutic goods in Australia. Section 16J of the Therapeutic Goods Regulations 1990 (the Regulations), under which this designation is made, allows for the recognition of orphan drugs, which are defined as those intended for the treatment of rare diseases or conditions. In this instance, nitric oxide (INOmax) has been designated as an orphan drug for the treatment of peri- and post-operative pulmonary hypertension in newborn infants, infants and toddlers, children and adolescents aged 0-17 years, in conjunction with heart surgery (Section 16J(2)). The designation of nitric oxide (INOmax) as an orphan drug imposes certain obligations on the parties involved. The sponsor, in this case, Ikaria Australia Pty Ltd, must ensure that the therapeutic good meets the required standards and is safe and effective for its intended use (Section 16J(3)). The sponsor is also required to provide information and data to support the designation, including evidence of the drug's efficacy and safety (Section 16J(4)). Additionally, the sponsor must ensure that the drug is manufactured, stored, and distributed in accordance with the relevant regulations and guidelines (Section 16J(5)). Failure to comply with the requirements of the Act and Regulations may result in civil or criminal penalties. Under the Act, a person who contravenes a provision of the Act or the Regulations may be subject to a civil penalty, which may include fines or other monetary penalties (Section 11A). In addition, a person who is found guilty of an offence under the Act or Regulations may be subject to criminal penalties, including fines and imprisonment (Section 11B). The maximum penalties for offences under the Act and Regulations vary depending on the nature and severity of the offence, but may include fines of up to $220,000 for individuals and $1,100,000 for bodies corporate, as well as imprisonment for up to five years (Sections 11A(2) and 11B(2)). In summary, the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 provide the legal framework for the regulation of therapeutic goods in Australia, including the designation of orphan drugs such as nitric oxide (INOmax). The Act imposes obligations on the sponsor of the drug to ensure that it meets the required standards and is safe and effective for its intended use. Failure to comply with the requirements of the Act and Regulations may result in civil or criminal penalties, including fines and imprisonment.